MoCA — Montreal Cognitive Assessment
30-point cognitive screening tool, more sensitive than the MMSE for mild cognitive impairment (Nasreddine 2005: cut-off 26 detected 90% of MCI and 100% of mild Alzheimer's disease).
How to use & interpret
The Montreal Cognitive Assessment (MoCA) is a 30-point screen that is more sensitive than the MMSE for mild cognitive impairment, testing executive function, attention, memory, language, visuospatial skills and orientation. A score of ≥26 is generally considered normal, and one point is added for people with 12 or fewer years of education.
It is a screening and monitoring tool, interpreted alongside history, functional impact and, where needed, further investigation — not a stand-alone diagnosis.
Score interpretation
MoCA ≥ 26 — normal cognitive performance
→ No specific cognitive intervention required; reassess if concerns arise clinically; repeat annually if risk factors for dementia present
MoCA < 26 — cognitive impairment possible. At this cut-off the MoCA detected 90% of mild cognitive impairment and 100% of mild Alzheimer's disease, with 87% specificity (Nasreddine 2005).
→ Full cognitive assessment and history from an informant; check reversible causes (thyroid, B12, folate, glucose, medication, mood); consider memory clinic referral; assess capacity, driving and safety; interpret in light of education, language and sensory impairment.
Interpretation bands for the MoCA. Apply clinical judgement and local guidance.
Frequently asked questions
MoCA or MMSE?
MoCA is more sensitive for mild cognitive impairment and executive dysfunction; MMSE is quicker and more familiar. MoCA is often preferred when early or subtle impairment is suspected.
References
- Nasreddine ZS et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
Related
Curated clinical cross-links plus same-class fallbacks.
- Confusion Assessment Method (CAM) · Cognitive Assessment
- Mini-Mental State Examination (MMSE) · Cognitive Assessment
- Mini-Mental State Examination (MMSE) · Cognitive Assessment
- 6-Item Cognitive Impairment Test (6CIT) · Cognitive Assessment
- Abbreviated Mental Test Score (AMT-10) · Cognitive Assessment
- Montreal Cognitive Assessment (MoCA) · Cognitive Assessment
- Donepezil · Acetylcholinesterase inhibitor (AChEI) — dementia
- Memantine · NMDA receptor antagonist — dementia
- Rivastigmine · Dual AChEI and BuChEI inhibitor — dementia
- Quetiapine (Elderly — Dementia Caution) · Atypical Antipsychotic
- Memantine · NMDA Receptor Antagonist — Dementia
- Rivastigmine · Acetylcholinesterase Inhibitor — Dementia
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.